nach oben

Erschienen in:

08.10.2018 | Affektlabilität | Zertifizierte Fortbildung

Komorbidität oder mehr?

Biologische Grundlagen bei ADHS und bipolarer Störung

verfasst von: Dr. med. habil. Sarah Kittel-Schneider

Erschienen in: NeuroTransmitter | Ausgabe 10/2018

Einloggen, um Zugang zu erhalten

Zusammenfassung

Die Aufmerksamkeitsdefizits-/Hyperaktivitätsstörung (ADHS) und die bipolare Störung sind nicht immer einfach voneinander abzugrenzen, relevante Komorbiditäten sind gut belegt. Derzeit wird diskutiert, ob die Komorbidität von ADHS und bipolarer Störung vielleicht sogar als Subtyp der bipolaren Störung gewertet werden sollte oder sogar als eigene Krankheitsentität. Die Erforschung der genetischen, neurobiologischen und hirnfunktionellen Gemeinsamkeiten und Unterschiede werden aber zukünftig dazu führen, dass die Diagnostik und Behandlung dieser Patienten verbessert werden kann.

Philipsen A, Hesslinger B and L. Tebartz van Elst, Attention deficit hyperactivity disorder in adulthood: diagnosis, etiology and therapy. Dtsch Arztebl Int, 2008. 105(17):311–7PubMedPubMedCentral

Fayyad J et al. Cross-national prevalence and correlates of adult attention-deficit hyperactivity disorder. Br J Psychiatry, 2007;190: 402–9CrossRef

Retz-Junginger P et al. Wender Utah rating scale. The short-version for the assessment of the attention-deficit hyperactivity disorder in adults. Nervenarzt 2002. 73(9): 830–8CrossRef

Gross-Lesch S et al. Sex- and Subtype-Related Differences in the Comorbidity of Adult ADHDs. J Atten Disord. 2016 Oct; 20(10): 855–66CrossRef

Jacob CP et al. Co-morbidity of adult attention-deficit/hyperactivity disorder with focus on personality traits and related disorders in a tertiary referral center. Eur Arch Psychiatry Clin Neurosci, 2007; 257(6): 309–17CrossRef

Ryden E et al. A history of childhood attention-deficit hyperactivity disorder (ADHD) impacts clinical outcome in adult bipolar patients regardless of current ADHD. Acta Psychiatr Scand 2009; 120(3): 239–46CrossRef

Merikangas KR et al. Lifetime and 12-month prevalence of bipolar spectrum disorder in the National Comorbidity Survey replication. Arch Gen Psychiatry 2007; 64(5): 543–52CrossRef

Brus MJ, Solanto M.V. Goldberg J.F. Adult ADHD vs. bipolar disorder in the DSM-5 era: a challenging differentiation for clinicians. J Psychiatr Pract 2014; 20(6): 428–37CrossRef

Wilens TE et al. yCan adults with attention-deficit/hyperactivity disorder be distinguished from those with comorbid bipolar disorder? Findings from a sample of clinically referred adults. Biol Psychiatry 2003; 54(1): 1–8CrossRef

10.

Goodman DW and M.E. Thase, Recognizing ADHD in adults with comorbid mood disorders: implications for identification and management. Postgrad Med 2009; 121(5): 20–30CrossRef

11.

Richard-Lepouriel H. et al. Similarities between emotional dysregulation in adults suffering from ADHD and bipolar patients. J Affect Disord 2016; 198: 230–6CrossRef

12.

McKnight, R.F., et al., Longitudinal mood monitoring in bipolar disorder: Course of illness as revealed through a short messaging service. J Affect Disord 2017; 223: 139–145CrossRef

13.

Skirrow C et al. Everyday emotional experience of adults with attention deficit hyperactivity disorder: evidence for reactive and endogenous emotional lability. Psychol Med, 2014; 44(16): 3571–83CrossRef

14.

Faraone, S.V., et al., Attention-deficit hyperactivity disorder with bipolar disorder: a familial subtype? J Am Acad Child Adolesc Psychiatry, 1997; 36(10): 1378–87; discussion 1387–90CrossRef

15.

McIntyre R., Bipolar disorder and ADHD: Clinical concerns. CNS Spectr 2009; 14(7 Suppl 6): 8–9; discussion 13–4CrossRef

16.

Bernardi S. et al., Bipolar disorder and comorbid attention deficit hyperactivity disorder. A distinct clinical phenotype? Clinical characteristics and temperamental traits. World J Biol Psychiatry 2010; 11(4): 656–66CrossRef

17.

Wang LJ et al., Attention-deficit hyperactivity disorder, its pharmacotherapy, and the risk of developing bipolar disorder: A nationwide population-based study in Taiwan. J Psychiatr Res 2016; 72: 6–14CrossRef

18.

Duffy A. et al., The developmental trajectory of bipolar disorder. Br J Psychiatry, 2014; 204(2): 122–8CrossRef

19.

Faraone SV J. Biederman, and J. Wozniak, Examining the comorbidity between attention deficit hyperactivity disorder and bipolar I disorder: a meta-analysis of family genetic studies. Am J Psychiatry 2012; 169(12): 1256–66CrossRef

20.

Weber H et al. Cross-disorder analysis of bipolar risk genes: further evidence of DGKH as a risk gene for bipolar disorder, but also unipolar depression and adult ADHD. Neuropsychopharmacology 2011; 36(10): 2076-85CrossRef

21.

Weber H et al. On the role of NOS1 ex1f-VNTR in ADHD-allelic, subgroup, and meta-analysis. Am J Med Genet B Neuropsychiatr Genet 2015; 168(6): 445–458CrossRef

22.

Lescai F. et al. Whole-exome sequencing of individuals from an isolated population implicates rare risk variants in bipolar disorder. Transl Psychiatry 2017; 7(2): e1034CrossRef

23.

Liu YS et al. The Association of SNAP25 Gene Polymorphisms in Attention Deficit/Hyperactivity Disorder: a Systematic Review and Meta-Analysis. Mol Neurobiol 2017; 54(3): 2189–2200CrossRef

24.

Houenou J et al. A Multilevel Functional Study of a SNAP25 At-Risk Variant for Bipolar Disorder and Schizophrenia. J Neurosci, 2017; 37(43): 0389–10397CrossRef

25.

Smoller JW et al. Identification of risk loci with shared effects on five major psychiatric disorders: a genome-wide analysis. Lancet, 2013; 381(9875): 1371–9CrossRef

26.

van Hulzen KJE. et al. Genetic Overlap Between Attention-Deficit/Hyperactivity Disorder and Bipolar Disorder: Evidence From Genome-wide Association Study Meta-analysis. Biol Psychiatry 2017; 82(9): 634–641CrossRef

27.

Freudenberg FA. Alttoa, and A. Reif, Neuronal nitric oxide synthase (NOS1) and its adaptor, NOS1AP, as a genetic risk factors for psychiatric disorders. Genes Brain Behav 2015; 14(1): 46–63CrossRef

28.

Maia-de-Oliveira JP. et al. Nitric Oxide’s Involvement in the Spectrum of Psychotic Disorders. Curr Med Chem 2016; 23(24): 2680–2691CrossRef

29.

Selek S. et al. The course of nitric oxide and superoxide dismutase during treatment of bipolar depressive episode. J Affect Disord, 2008; 107(1–3): 89–94CrossRef

30.

Selek S et al. Probable oxidative imbalance in bipolar depression: The course of nitric oxide and superoxide during the treatment of episode. Bipolar Disorders, 2006; 8: 66–66

31.

Selek S et al., Oxidative imbalance in adult attention deficit/hyperactivity disorder. Biol Psychol 2008; 79(2): 256–9CrossRef

32.

Nasyrova RF et al. Role of nitric oxide and related molecules in schizophrenia pathogenesis: biochemical, genetic and clinical aspects. Front Physiol 2015; 6: 139CrossRef

33.

Kittel-Schneider, S. et al. Multi-level biomarker analysis of nitric oxide synthase isoforms in bipolar disorder and adult ADHD. J Psychopharmacol 2015; 29(1): 31–8CrossRef

34.

Baird AL et al., Adult attention-deficit hyperactivity disorder is associated with alterations in circadian rhythms at the behavioural, endocrine and molecular levels. Mol Psychiatry 2012; 17(10): 988–95CrossRef

35.

Landgraf D. McCarthy M.J., and D.K. Welsh. Circadian clock and stress interactions in the molecular biology of psychiatric disorders. Curr Psychiatry Rep 2014; 16(10): 483CrossRef

36.

Seleem MA et al. The longitudinal course of sleep timing and circadian preferences in adults with bipolar disorder. Bipolar Disord 2015; 17(4): 392–402CrossRef

37.

Kittel-Schneider S. et al. Lithium-induced Clock Gene Expression in Lymphoblastoid Cells of Bipolar Affective Patients. Pharmacopsychiatry 2015; 48(4–5): 145–9PubMed

38.

Yang, S et al. Assessment of circadian function in fibroblasts of patients with bipolar disorder. Mol Psychiatry 2009; 14(2): 143–55CrossRef

39.

Palsson E et al. Cerebrospinal fluid monoamine metabolite profiles in bipolar disorder, ADHD, and controls. J Neural Transm (Vienna) 2017 Sep; 124(9): 1135–1143CrossRef

40.

Ryden E., et al., Lower CSF HVA and 5-HIAA in bipolar disorder type 1 with a history of childhood ADHD. J Neural Transm (Vienna), 2009. 116(12): p. 1667–74CrossRef

41.

Phillips ML and H.A. Swartz. A critical appraisal of neuroimaging studies of bipolar disorder: toward a new conceptualization of underlying neural circuitry and a road map for future research. Am J Psychiatry 2014; 171(8): 829–43CrossRef

42.

Townsend JD et al. Frontal-amygdala connectivity alterations during emotion downregulation in bipolar I disorder. Biol Psychiatry 2013; 73(2): 127–35CrossRef

43.

Shaw P et al. Emotion dysregulation in attention deficit hyperactivity disorder. Am J Psychiatry 2014; 171(3): 276–93CrossRef

44.

Passarotti AM J.A. Sweeney, and M.N. Pavuluri. Differential engagement of cognitive and affective neural systems in pediatric bipolar disorder and attention deficit hyperactivity disorder. J Int Neuropsychol Soc 2010; 16(1): 106–17CrossRef

45.

Hafeman D et al. Amygdala-prefrontal cortical functional connectivity during implicit emotion processing differentiates youth with bipolar spectrum from youth with externalizing disorders. J Affect Disord 2017; 208: 94–100CrossRef

46.

Townsend JD et al. Frontostriatal neuroimaging findings differ in patients with bipolar disorder who have or do not have ADHD comorbidity. J Affect Disord 2013; 147(1–3): 389–96CrossRef

47.

Asherson P et al. Differential diagnosis, comorbidity, and treatment of attention-deficit/hyperactivity disorder in relation to bipolar disorder or borderline personality disorder in adults. Curr Med Res Opin 2014; 30(8): 1657–72CrossRef

48.

Viktorin A et al. The Risk of Treatment-Emergent Mania With Methylphenidate in Bipolar Disorder. Am J Psychiatry 2017; 174(4): 341–348CrossRef

49.

Szmulewicz AG et al. Dopaminergic agents in the treatment of bipolar depression: a systematic review and meta-analysis. Acta Psychiatr Scand 2017; 135(6): 527–538CrossRef

50.

Geissler J et al. Hyperactivity and sensation seeking as autoregulatory attempts to stabilize brain arousal in ADHD and mania? Atten Defic Hyperact Disord 2014; 6(3): 159–73CrossRef

51.

Hegerl U et al. A multi-centre,randomised, double-blind, placebo-controlled clinical trial of methylphenidate in the initial treatment of acute mania (MEMAP study). Eur Neuropsychopharmacol 2018; 28(1): 185–194CrossRef

Titel: Komorbidität oder mehr?
Biologische Grundlagen bei ADHS und bipolarer Störung
verfasst von: Dr. med. habil. Sarah Kittel-Schneider
Publikationsdatum: 08.10.2018
Verlag: Springer Medizin
Schlagwörter: Affektlabilität
ADHS
ADHS
Erschienen in: NeuroTransmitter / Ausgabe 10/2018
Print ISSN: 1436-123X
Elektronische ISSN: 2196-6397
DOI: https://doi.org/10.1007/s15016-018-6216-0

Leitlinien kompakt für die Neurologie

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Neurologie

23.04.2024 | Demenz | Nachrichten

Update Neurologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Biologische Grundlagen bei ADHS und bipolarer Störung

Zusammenfassung

Leitlinien kompakt für die Neurologie

Neu im Fachgebiet Neurologie

Demenzkranke durch Antipsychotika vielfach gefährdet

Parkinson-Therapie im Wandel – aktuelle Leitlinie im Fokus

Auf diese Krankheiten bei Geflüchteten sollten Sie vorbereitet sein

Hustenstiller lindert Agitation bei Alzheimer

Update Neurologie

Springer Medizin

Zusammenfassung

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 10/2018

Gebührenordnungssysteme: Reformmotor stottert weiter

Den Generationswechsel meistern

„Nationale Demenzstrategie“ gestartet

Neue Wege für Kinder mit MS — und für Patienten mit progredienter MS

Kein Anspruch auf Terminvermittlung durch auswärtige KV

Petition zur Fristverlängerung bei Telematikinfrastruktur

Leitlinien kompakt für die Neurologie

Neu im Fachgebiet Neurologie

Demenzkranke durch Antipsychotika vielfach gefährdet

Parkinson-Therapie im Wandel – aktuelle Leitlinie im Fokus

Auf diese Krankheiten bei Geflüchteten sollten Sie vorbereitet sein

Hustenstiller lindert Agitation bei Alzheimer

Update Neurologie